10:21 , Aug 24, 2017 |  BC Innovations  |  Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...
07:00 , Jul 14, 2016 |  BC Innovations  |  Product R&D

Apogenix's hex on TNF

TNF receptor superfamily members include well-validated cancer and immuno-oncology drug targets, but creating high-potency agonists is made difficult by the molecules' unique mode of ligand binding. Apogenix AG is designing compounds that more closely mimic...
07:00 , Oct 26, 2015 |  BioCentury  |  Strategy

Collaborating on combos

As oncologists and drug developers converge on the idea that combination therapies built on a backbone of PD-L1 or PD-1 inhibitors could lead to cures for some cancers, or keep them at bay for years,...
07:00 , Jun 4, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Immunoglobulin G (IgG)

Cancer INDICATION: Cancer Cell culture and mouse studies suggest allogeneic IgG could enhance the efficacy of immunotherapies for cancer. In co-cultures of mouse dendritic cells (DCs) and T cells mixed with lysates of mouse melanoma or pancreatic...
07:00 , Aug 12, 2013 |  BioCentury  |  Finance

Abiding no more

Abiding no more Unable to raise venture money when it spun out of service play Epitomics Inc. in 2010, Apexigen Inc. was able to work for three years using $2 million in seed funding plus partnership...
00:05 , Aug 7, 2013 |  BC Extra  |  Financial News

Apexigen raises $20 million in A round

Apexigen Inc. (Burlingame, Calif.) raised $20 million in a series A round led by Amkey Ventures. WSR Capital; China Development Industrial Bank; Themes Investment Partners; and Sycamore Ventures also participated. Amkey's George Lee joined Apexigen's...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Company News

PanGenetics, Abbott deal

Abbott will acquire worldwide rights to PG110 from PanGenetics for an upfront payment of $170 million, plus up to $20 million in potential milestones. The humanized antibody that binds to nerve growth factor...
07:00 , May 7, 2009 |  BC Innovations  |  Targets & Mechanisms

IL-15's arranged marriage

Although Novartis AG's recombinant IL-2, Proleukin aldesleukin, is one of the few FDA-approved drugs for metastatic melanoma and renal cell carcinoma, use of the drug is limited because of its severe side effects and limited...
08:00 , Feb 25, 2008 |  BC Week In Review  |  Company News

Alligator Bioscience, ImmuRx deal

Alligator will use its protein optimization technology to develop a CD40 agonist for use in ImmuRx's cancer adjuvant platform. ImmuRx will have rights to resulting products. Alligator will receive undisclosed fees and is eligible...
07:00 , May 6, 2002 |  BC Week In Review  |  Clinical News

ISF154: Tragen began a U.S. dose-ranging Phase II trial of its ISF154 as a monotherapy in 2 cohorts of 20 patients with CLL. In the first cohort, patients refra

Tragen Pharmaceuticals Inc., San Diego, Calif.   Product: ISF154   Business: Cancer   Therapeutic category: Immune stimulation   Target: CD40 receptor on B-cells   Description: CD40 agonist   Indication: Treat chronic lymphocytic leukemia (CLL)   Endpoint: Reduction in leukemia cells...